Overview: Procollagen Type III N-Terminal Propeptide TestIntroduction: The Procollagen Type III N-Terminal Propeptide Test measures PIIINP to diagnose liver or bone disorders, causing jaundice or fractures. Following 2023 AASLD guidelines, it uses biochemical methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected liver fibrosis or bone disorders.
Other Names: PIIINP Assay, Liver/Bone Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: PIIINP testing began in the 1980s with fibrosis research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures PIIINP to diagnose liver or bone disorders, guides treatment, and evaluates patients with jaundice or fractures.
Test Parameters: 1. PIIINP Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma. Report history of jaundice, fractures, or liver/bone symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fractures, or history of liver/bone disorders. Include current medications, especially antifibrotics or bisphosphonates.
Consent: Written consent required, detailing the tests purpose, liver/bone disorder implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to measure PIIINP levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for liver or bone disorder diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper fasting can affect results. Recent liver injury may elevate PIIINP levels.
Clinical Significance: Elevated PIIINP confirms liver fibrosis or bone disorders, guiding antifibrotic therapy or bone treatment. Normal results may require liver biopsy or bone density testing.
Specialist Consultation: Consult a hepatologist or orthopedist for result interpretation and treatment planning.
Additional Supporting Tests: Liver function tests, bone density scan, or FibroScan to confirm liver/bone disorder diagnosis.
Test Limitations: Non-specific for certain disorders; clinical correlation is needed. Sample quality affects sensitivity.
References: AASLD Fibrosis Guidelines, 2023; Hepatology, Schuppan D, 2022.
